I think my multi-month theory on that trial’s use fits. I don’t disagree with your post I’m responding to. Except I think Roswell would be most cooperative. They are not inconsistent.
Could be a red flag but I suspect it’s doing well. They’ve figured out ideal delivery in terms of timing and dosing. I suspect LP wishes she had a do over on the Plll.
What kind of results can you expect on Survaxm? I can tell there is only one result pending for Survaxm: Failure. What is the target Survaxm chose? Is it survivin?
If you read Dr. Liau's papers, you should know that Dr. Liau conducted a trial by loading DCs with peptides derived from antigens TRP-2, gp100, her-2/neu, and survivin. The trial results cannot outperform those from the approach which adopted tumor-lysate. Clearly, Survaxm cannot beat DCVax-L.
Are you guys still talking about the p3 trial? Have you seen Dr. Liau was involved in every important aspect of the p3 trial? Next time watch the following news first before talking about the p3 trial.
BTW, do you see FDA finally is getting back the commonsense? To be honest, I already have a foretaste of generational wealth in my mind.